<?xml version="1.0" encoding="UTF-8"?>
<ref id="B41-biomedicines-08-00060">
 <label>41.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Sato-Dahlman</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Miura</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>J.L.</given-names>
   </name>
   <name>
    <surname>Hajeri</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Jacobsen</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Davydova</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Yamamoto</surname>
    <given-names>M.</given-names>
   </name>
  </person-group>
  <article-title>CD133-targeted oncolytic adenovirus demonstrates anti-tumor effect in colorectal cancer</article-title>
  <source>Oncotarget</source>
  <year>2017</year>
  <volume>8</volume>
  <fpage>76044</fpage>
  <lpage>76056</lpage>
  <pub-id pub-id-type="doi">10.18632/oncotarget.18340</pub-id>
  <pub-id pub-id-type="pmid">29100290</pub-id>
 </element-citation>
</ref>
